All In Biotech

Drug Trial Radar · NCT06469411

Effect of PMSCs and Their Secretome for the Treatment of GvHD

The Effect MSCs Derived From the Placenta and Their Secretome for the Treatment of GvHD: A Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jun 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

60

Actual

Start

Jan 1, 2023

Primary completion

Jun 30, 2023

Study completion Jan 30, 2024

Sponsor

Lead sponsor
Tabriz University of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
SCARM Institute, Tabriz, Iran
First posted
Jun 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this clinical trial study, 60 patients with GvHD referred to Shahid Qazi Hospital in Tabriz, were randomly divided into 2 intervention and control groups (n= 30 in each) that received secretome and distilled water by injection, respectively. The method of blinding was triple-blinded and all the names and personal information of the patients were coded at the time of data collection and remained completely confidential.

Conditions

  • GVHD

Interventions

  • Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter)Biological

    Patients in the intervention arm received 6 doses of secretome of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) 4 cc dissolved in albumin 20% every week for 6 weeks

  • 4 cc distilled water dissolved in albumin 20%Other

    Patients in the control arm received 6 doses of 4 cc distilled water dissolved in albumin 20% every week for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Liver involvementTime frame: At the beginning of the study and 6 weeks after the intervention
  2. Intestine conditionTime frame: At the beginning of the study and 6 weeks after the intervention
  3. Skin rashTime frame: At the beginning of the study and 6 weeks after the intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Abolfazl Barzegari

    Tabriz, East Azerbaijan Province, Iran

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.